Sionna Therapeutics, Inc. Overview
Pro stress-test →Sionna Therapeutics is a clinical-stage biopharmaceutical company researching and developing medicines for the treatment of cystic fibrosis (CF). The company focuses on novel CFTR modulators targeting the F508del mutation, the most common CF genetic variant, with multiple candidates in clinical development.
Strategic Profile
Pro stress-test →The company ended fiscal year 2025 with $310.3 million in cash and guided its cash runway until 2028. Analysts highlight potential in Sionna's CF drug candidates, particularly the NBD1 stabilizers SION-719 and SION-451, with proof-of-concept readouts anticipated by mid-2026.
Competitive Landscape
Pro stress-test →Sionna competes in the cystic fibrosis therapeutic space against established players like Vertex Pharmaceuticals (VERTEX - Kalydeco, Orkambi, Trikafta) and emerging biotech companies. Sionna's differentiation centers on NBD1-directed CFTR stabilization approach targeting the most common F508del mutation, representing potential competitive advantage in monotherapy and combination therapy paradigms.
Industry Context
Sionna Therapeutics, Inc. operates in Biopharmaceutical - Specialty Therapeutics (Cystic Fibrosis).
Key facts
Founded: 2019 · Headquarters: Waltham, Massachusetts · Market cap: $1.51B